Skip to main content

Table 4 Age-specific comparison of standard gamble utility scores converted using the ‘12 month-early stage cervical cancer’ score

From: A survey of population-based utility scores for cervical cancer prevention

Health state Age groups Wilcoxan rank sum test P value
20-49 years 50-69 years
Mean utility score Median utility score (IQR) Mean utility score Median utility score
(SE)   (SE) (IQR)
Cytology normal 0.9938 0.9997 0.9990 0.9999 0.4932
(0.0055) (0.9994 - 1.0) (0.0004) (0.9994 - 1.0)
HPV vaccination 0.9992 0.9998 0.9539 1.0 0.6534
( 0.0004) (0.9994 - 1.0) ( 0.0454) (0.9996 - 1.0)
LG cytology 0.9935 0.9997 0.9563 0.9998 0.2855
(0.0055) (0.9993 - 0.9999) (0.0429) (0.9996 - 1.0)
LG cytology with colposcopy normal 0.9909 0.9997 0.9563 0.9997 0.3383
(0.0070) (0.9950 - 0.9999) (0.0420) (0.9969 - 1.0)
HPV positive with cytology normal 0.9942 0.9997 0.9552 0.9997 0.3379
(0.003955) (0.9959 - 0.9999) ( 0.0434) (0.9977 - 1.0)
HPV positive with colposcopy normal 0.9934 0.9997 0.9990 0.9998 0.1280
( 0.0045) (0.9950 - 0.9999) (0.0004) (0.9989 - 0.9999)
Treated genital warts 0.9894 0.9997 0.9532 0.9997 0.2483
( 0.0056) (0.9950 - 0.9999) ( 0.0454) (0.9990 - 1.0)
HG cytology with CIN 1 0.9956 0.9997 0.9523 0.9996 0.3725
( 0.0024) (0.9950 - 0.9997) (0.0420) (0.9977 - 0.9999)
HG cytology with CIN 2 or 3 0.9908 0.9995 0.9527 0.9996 0.2826
(0.0049) (0.9948 - 0.9997) (0.0433) (0.9983 - 1.0)
Early stage cervical cancer 0.7977 0.9450 0.8352 0.960 0.2616
(0.0819) (0.8850 - 0.9750) (0.0709) (0.915 - 0.995)
  1. HPV human papillomavirus; LG low grade disease; HG high grade disease; CIN cervical intraepithelial neoplasia; FIGO Fédération Internationale de Gynécologie Obstétrique (International Federation of Gynecology and Obstetrics.